Head-To-Head Analysis: TuHURA Biosciences (NASDAQ:HURA) and Enveric Biosciences (NASDAQ:ENVB)

Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 3.2% of Enveric Biosciences shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Enveric Biosciences and TuHURA Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$17.29 million	($2.56)	-0.15
TuHURA Biosciences	N/A	N/A	-$8.32 million	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Enveric Biosciences and TuHURA Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	0	0	1	0	3.00
TuHURA Biosciences	0	0	2	1	3.33

Enveric Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 2,565.25%. TuHURA Biosciences has a consensus target price of $13.00, suggesting a potential upside of 201.62%. Given Enveric Biosciences’ higher possible upside, equities research analysts clearly believe Enveric Biosciences is more favorable than TuHURA Biosciences.

Profitability

This table compares Enveric Biosciences and TuHURA Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-221.54%	-164.32%
TuHURA Biosciences	N/A	N/A	-152.88%

Risk & Volatility

Enveric Biosciences has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Summary

TuHURA Biosciences beats Enveric Biosciences on 7 of the 10 factors compared between the two stocks.

About Enveric Biosciences

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

About TuHURA Biosciences

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.